Practice Guideline Update · 2026 AHA/ACC Acute PE
PE does not suffer from a shortage of scoring systems. It suffers from too many of them.
AI Clinical Teaching Podcast · 6½ minutes
Listen: Pulmonary Embolism in 2026 — One Practical Pathway
A concise audio walkthrough of the diagnostic scores, A–E severity framework, anticoagulation, and advanced-therapy decisions in this guideline update.
AI-narrated educational summary based on the source pathway. Verify important clinical decisions against the complete guideline and patient-specific context.
SMART Brevity: the signal first
Why it matters: Across diagnosis, prognosis, disposition, bleeding risk, pregnancy, cancer, and advanced-therapy assessment, clinicians may encounter roughly 15–20 validated or commonly used PE tools. The challenge is not memorizing them. The challenge is knowing which clinical decision each tool is supposed to answer.
The Pearl: Probability picks the test; the A–E category picks the treatment.
Practical sequence: 1) estimate pretest probability → 2) choose D-dimer or imaging → 3) confirm PE and assign AHA/ACC A–E severity → 4) match disposition and anticoagulation → 5) decide whether advanced therapy belongs on the table.
Acute PE Pathway · At a Glance
Probability picks the test; the A–E category picks the treatment
Read top to bottom: probability → test → category → treatment.
Suspected PE in the ED
Vitals, SpO₂, ECG, focused exam
↓
Shock or hypotension?
No → Step 1: estimate pretest probability. PERC if gestalt <15%; otherwise Wells, Geneva, YEARS, or PEGeD. Pregnancy: adapted YEARS or Geneva, leg ultrasound first.
Yes → Unstable path
Bedside echo: RV size. CTPA once safe to move. Then Category D or E.
↓
Pretest <50% → D-dimer
Age × 10 cutoff if over 50. YEARS: 1000 or 500 cutoff.
Below cutoff → PE excluded; look for another diagnosis.
Above cutoff → CTPA.
Pretest ≥50% → CTPA
V/Q SPECT if contrast unsafe. Pregnancy: chest X-ray, then V/Q or CTPA. Cancer: often skip D-dimer.
PE confirmed → assign AHA/ACC category.
↓
Step 3 · AHA/ACC category, lowest to highest risk
Incidental, asymptomatic
sPESI 0, PESI ≤85; B1 subsegmental, B2 larger vessels
C1 RV/labs normal; C2 RV or labs; C3 RV and labs
D1 transient hypotension; D2 normotensive shock
E1 cardiogenic shock; E2 refractory shock or arrest
A: DOAC at home
No admission
B: DOAC
Early discharge
C: Admit, LMWH
PERT; advanced therapy selectively
D: PERT, LMWH
Lysis/CDT/MT/surgery may be considered
E: Advanced therapy
E2: VA-ECMO may be considered
Step 4 · Every patient
DOAC over warfarin; treat 3–6 months and extend if unprovoked or a risk factor persists. Cancer: DOAC or LMWH. Pregnancy: weight-based LMWH. Assess bleeding risk before lysis and before extended anticoagulation. IVC filter only when anticoagulation is absolutely contraindicated. Ask about dyspnea at every visit for 1 year.
Do not memorize every PE score—memorize the question it answers
| Clinical question | Useful tools | What the answer changes |
|---|---|---|
| Do I need testing, and which test? | PERC, Wells, Geneva, YEARS, PEGeD | D-dimer versus direct imaging |
| How sick is this patient? | PESI, sPESI, Bova | Severity, monitoring, admission intensity |
| Can this patient safely go home? | Hestia | Outpatient treatment versus admission |
| What is the bleeding risk if lysis is considered? | BACS, PE-CH | Risk-benefit discussion for thrombolysis |
| What is the bleeding risk if anticoagulation is extended? | VTE-BLEED | Long-term anticoagulation decision |
| What treatment intensity is appropriate? | 2026 AHA/ACC A–E category | Disposition, anticoagulation, PERT, reperfusion strategy |
Step 1 — Pretest probability before any test
If the patient is hypotensive or in shock, skip routine scoring and move directly to bedside assessment, stabilization, and definitive imaging once safe. Otherwise, estimate pretest probability with clinical gestalt plus one validated rule.
- PERC: use only when gestalt is already low (<15%); all eight negative means no D-dimer is needed.
- Wells: a practical default for many ED patients.
- Simplified revised Geneva: useful when an objective rule is preferred.
- YEARS: integrates three clinical items with a variable D-dimer threshold.
- PEGeD: uses Wells-based clinical probability to adjust the D-dimer cutoff.
Practical branch point: low or moderate probability generally moves toward D-dimer; high probability or strong gestalt moves directly to imaging. In high-probability patients with low bleeding risk, anticoagulation may be started while awaiting CTPA.
Step 2 — D-dimer or straight to imaging
For low- or moderate-probability patients, use a high-sensitivity D-dimer with an adjusted cutoff. For high-probability patients, skip D-dimer and proceed to CTPA.
- Age-adjusted D-dimer: age × 10 ng/mL FEU for patients older than 50; otherwise 500 ng/mL.
- YEARS: no YEARS items → cutoff 1000 ng/mL; one or more items → cutoff 500 ng/mL.
- Imaging: CTPA is preferred. If contrast is unsafe, V/Q SPECT is an alternative.
- Pregnancy: leg symptoms → compression ultrasound first; pregnancy-adapted YEARS or Geneva can be used, followed by chest imaging when still indicated.
- Cancer: D-dimer is less efficient because baseline values are often elevated; many patients go directly to imaging.
Step 3 — Assign the 2026 AHA/ACC A–E category
Once PE is confirmed, the new framework asks four practical questions: Is there shock or hypotension? Is the severity score low? Is the RV abnormal? Is troponin or BNP abnormal?
| Category | Clinical meaning | Key features |
|---|---|---|
| A | Subclinical | Incidental, asymptomatic |
| B1/B2 | Symptomatic, low severity | Subsegmental or larger PE with low severity score |
| C1 | Elevated severity | Normal RV and biomarkers |
| C2 | Higher-risk C | Abnormal RV or one abnormal biomarker |
| C3 | Higher-risk C | Abnormal RV and at least one abnormal biomarker |
| D1 | Transient hypotension | Brief or fluid-responsive hypotension |
| D2 | Normotensive shock | Hypoperfusion despite preserved blood pressure |
| E1 | Cardiogenic shock | Persistent or recurrent hypotension with shock |
| E2 | Refractory shock/arrest | Shock despite support or cardiac arrest |
Respiratory modifier: append “R” when significant hypoxemia or ventilatory failure is present. This is especially useful in patients who look severe despite preserved blood pressure.
PERT: categories C–E should trigger multidisciplinary pulmonary embolism response team involvement when available.
Step 4 — Match anticoagulation and disposition to category
- A–B: DOAC therapy with home treatment or early discharge when appropriate; use Hestia if outpatient safety is uncertain.
- C–E: hospitalized patients generally receive LMWH; UFH is useful when advanced therapy, a procedure, or severe renal failure is likely.
- Oral phase: DOACs are preferred over warfarin unless contraindicated.
- Duration: treat for at least 3–6 months; extend therapy when the event was unprovoked or a risk factor persists.
- IVC filter: reserve for an absolute contraindication to anticoagulation, with retrieval once anticoagulation can be started.
Special populations: in active cancer, apixaban, edoxaban, rivaroxaban, or LMWH are options; apixaban or LMWH may be preferable in luminal GI/GU tumors. In pregnancy, use weight-based LMWH; DOACs and warfarin are avoided during pregnancy.
Step 5 — When advanced therapy enters the discussion
Advanced therapy becomes increasingly relevant from C3 upward and should be individualized with PERT when available.
- A–C2: anticoagulation alone; systemic lysis is harmful in lower-risk disease.
- C3: selected patients may be considered for systemic lysis, catheter-directed lysis, or mechanical thrombectomy, but benefit remains uncertain.
- D1–D2: systemic lysis, catheter-directed therapy, mechanical thrombectomy, or surgical embolectomy may be considered depending on bleeding risk, anatomy, expertise, and deterioration.
- E1: advanced reperfusion therapies are reasonable, with vasopressor/inotrope support.
- E2: VA-ECMO may be reasonable when resources and expertise exist.
Mechanical thrombectomy avoids fibrinolytic drug exposure and is particularly attractive when thrombolysis is contraindicated. Surgical embolectomy remains an option when lysis is contraindicated or has failed, especially when local expertise is strong.
Follow-up matters
Ask about dyspnea and functional limitation at every visit for at least one year to screen for chronic thromboembolic pulmonary disease.
Clinical use: This article is an educational interpretation of the attached 2026 PE pathway. Individual management should incorporate patient-specific factors, local resources, contraindications, and the complete guideline before local adoption.
Key sources
- Creager MA, et al. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for Acute Pulmonary Embolism. J Am Coll Cardiol. 2026;87(13):1626–1710.
- Dudzinski DM, et al. 2026 Acute PE Guideline-at-a-Glance. J Am Coll Cardiol. 2026;87(13):1620–1625.
- Bikdeli B. AHA/ACC Guideline on Pulmonary Embolism. NEJM Journal Watch. 2026.
Downloadable Clinical Pathway
Acute PE Pathway: ED to Treatment (2026)
Download the 4-page reference pathway for bedside review, teaching, or personal study.
